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Introduction: Approximately 2% of lung adenocarcinomas have 
BRAF (v-Raf murine sarcoma viral oncogene homolog B) muta-
tions, including V600E and other types. Vemurafenib, dabrafenib, and 
sorafenib as BRAF inhibitors are currently tested in clinical trials, but 
access for patients is limited. The aim of this study was to document 
the clinical course of patients treated outside of clinical trials.
Methods: We conducted a retrospective multicenter cohort study in 
Europe of patients with advanced BRAF-mutant lung cancer treated 
with known BRAF inhibitors. Data were anonymized and centrally 
assessed for age, gender, smoking, histology, stage, local molecular 
diagnostic results, systemic therapies, and survival. Best response 
was assessed locally by RECIST1.1.
Results: We documented 35 patients treated in 17 centers with 
vemurafenib, dabrafenib, or sorafenib. Median age was 63 years 
(range 42–85); gender was balanced; 14 (40%) were never smokers; 
all (100%) had adenocarcinoma; 29 (83%) had V600E; 6 (17%) had 
other mutations; one of them had a concomitant KRAS mutation. 
Thirty (86%) patients had chemotherapy in the first line. Overall sur-
vival with first-line therapy was 25.3 months for V600E and 11.8 
months for non-V600E. Thirty-one patients received one BRAF 
inhibitor, and four received a second inhibitor. Overall response 
rate with BRAF therapy was 53%, and disease control rate was 
85%. Median progression-free survival with BRAF therapy was 5.0 
months, and overall survival was 10.8 months.
Conclusions: These results confirm the activity of targeted therapy in 
patients with BRAF-mutant lung adenocarcinoma. Further trials are war-
ranted to study combination therapies and drug resistance mechanisms.
Key Words: Lung cancer, Targeted therapy, BRAF, Vemurafenib, 
Dabrafenib.
(J Thorac Oncol. 2015;10: 1451–1457)
Lung cancer is the leading cause of cancer-related death in Europe.1 The majority (80–90%) of patients with lung can-
cer are current or former smokers, and most (70%) patients 
present with advanced stage at the time of the diagnosis, where 
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palliative chemotherapy is the standard-of-care.2 Prognosis 
remains poor, and new therapies are needed. Approximately 
15–20% of Caucasian patients (mainly the never-smokers) have 
tumors harboring epidermal growth factor receptor (EGFR) 
mutations (10–13%) or anaplastic lymphoma kinase (ALK) 
rearrangements (3–7%) and can benefit from targeted therapy 
with oral tyrosine kinase inhibitors. Several EGFR and ALK 
inhibitors are approved, based on randomized clinical trials 
showing superiority over conventional chemotherapy.3 Further 
potentially druggable targets include c-ros oncogene 1 (ROS1) 
and rearranged during transfection (RET) rearrangements, 
hepatocyte growth factor receptor (MET) amplification, and 
human epidermal growth factor receptor 2 (HER2) and BRAF 
(v-Raf murine sarcoma viral oncogene homolog B) mutations.4 
These alterations are less frequent (1–3%) than EGFR muta-
tions or ALK rearrangements, and clinical experience with tar-
geted therapy is often limited to case reports or small series.
The BRAF gene encodes the serine/threonine-protein 
kinase BRAF, which regulates normal cell growth and pro-
liferation.5 The kinase domain of BRAF is encoded by the 
amino acid residues 457–717. In the inactive conformation, 
the activation loop (residues 596–600) interacts with the 
P-loop, locking the kinase. Phosphorylation of the activation 
loop transforms the kinase into the active state, and B-Raf can 
activate the mitogen activated kinase-like protein (MAPK) 
signaling pathway.6 BRAF is frequently mutated in cancer, 
with highest mutation rates in hairy cell leukemia (100%), 
malignant melanoma (>60%), and papillary thyroid can-
cer (>50%).7–9 The most frequent BRAF mutation in cancer 
overall is V600E, leading to constitutive activation of B-Raf 
kinase and its downstream target extracellular regulated MAP 
kinase (ERK), whereas other BRAF mutations have also been 
described.7 The clinical development of BRAF V600E spe-
cific small inhibitors was pioneered in the field of melanoma, 
with two drugs (vemurafenib and dabrafenib) approved for the 
treatment of patients with advanced disease.10,11
BRAF is mutated in 1% to 3% of lung cancers, predomi-
nantly in lung adenocarcinoma.12–20 A large study by the U.S. 
Lung Cancer Mutation Consortium included 951 lung adenocar-
cinomas, 21 (2.2%) were BRAF-mutant, 17 of them had V600E, 
and 4 had non-V600E mutations.20 We and others previously 
reported responses to vemurafenib in individual patients with 
BRAF-mutant lung cancer.21–24 Dabrafenib induced responses 
in a phase I trial in patients with BRAF-mutant melanoma and 
other solid tumors, including lung cancer.25 Sorafenib exceeded 
the prespecified efficacy end point (8-week disease control rate) 
in patients with Kristen rat sarcoma oncogene (KRAS) or BRAF 
mutant lung cancer in the Biomarker-integrated Approaches of 
Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.26 
However, clinical experience with BRAF inhibitors in patients 
with lung cancer remains limited. We conducted this study to 
collect and analyze data from patients with BRAF-mutant lung 
cancer receiving targeted therapy outside of a clinical trial.
PATIENTS AND METHODS
Patients and Ethical Considerations
Eligibility criteria for this study were diagnosis of 
non–small-cell lung cancer (NSCLC) by local pathology 
(all histological subtypes), advanced stages III and IV by 
the 7th TNM classification, BRAF mutation by local testing 
(including V600E and non-V600E), and at least one line of 
therapy with a commercial BRAF inhibitor. Local laborato-
ries had to be accredited, quality controlled, and could use 
any established test method, including Sanger sequencing or 
next generation sequencing (NGS). Reports had to be avail-
able as written documents. Contributors were responsible for 
patient information, consent, and institutional review board 
approval, according to local regulations.
Treatment and Follow-up
Only patients treated with a BRAF inhibitor outside 
of a clinical trial were accepted in our study. Based on the 
regulatory situation in Europe in 2012–2014, commercially 
available BRAF inhibitors were vemurafenib, dabrafenib, 
and sorafenib. Patients treated with MEK inhibitors, or 
treated in clinical trials with BRAF or MEK inhibitors, 
were excluded from our study. Computed tomography 
scans were performed every 2–4 months. Brain imaging 
was done in the presence of symptoms, or in patients with 
known brain metastases.
Data Collection
Between October and December 2014, the study 
coordinator (J.M.) registered all patients in a central data-
base and collected anonymized data from the participating 
centers, including patient characteristics (age at diagnosis, 
gender, smoking, survival status), tumor parameters (his-
tology, stage at diagnosis, metastatic sites, BRAF muta-
tion type), and systemic therapies (generic drug names, 
start date, end date, best response by Response Evaluation 
Criteria in Solid Tumors (RECIST) 1.1 on local assessment, 
duration of therapy). Unexpected or fatal adverse events 
were also noted. The database was updated in January and 
February 2015 and locked for the statistical analysis on 
February 28, 2015.
Statistics
All calculations were performed by independent stat-
isticians (B.C. and T.F.). Categorical variables were pre-
sented as contingency tables, ie, number and percentage 
for each category of variable and number of missing data. 
Quantitative variables were presented as median, range, and 
missing data. Survival data were summarized by the Kaplan–
Meier method with 95% confidence intervals. Progression-
free survival (PFS) was defined as the time between the 
date of start of treatment (either chemotherapy or targeted 
anti-BRAF treatment) and the date of tumor progression 
or death. Patients alive and progression free at the date of 
the last follow-up were censored. Overall survival (OS) was 
defined as the time between the date of start of treatment 
(either chemotherapy or targeted–anti-BRAF treatment) and 
the date of death. Patients alive at the date of last follow-up 
were censored. The main endpoints of the study were overall 
response rate (ORR) and PFS for BRAF therapy. Statistical 
analysis was performed under STATA Version 13 software 
(Stata Corporation, College Station, TX).
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RESULTS
Patient Characteristics and Tumor Parameters
We collected data from 35 eligible patients from 17 
centers in five different countries, including France (13), 
Switzerland (10), Germany (7), the Netherlands (4), and 
Austria (1; Table 1). Median age was 63 years (range, 42–85 
years); gender was balanced; 40% were never smokers; and 
46% were current or former smokers. All (100%) patients 
had lung adenocarcinoma histology; 34 (97%) had advanced 
tumor stage (III/IV) at the time of initial diagnosis; 1 had 
early disease at the time of the initial diagnosis (Table 2). Ten 
patients had malignant effusion, and six had brain metastases. 
By definition, all patients had a BRAF mutation, 29 (83%) 
V600E, and 6 (17%) non-V600E, including G466V, G469A, 
G469L, G596V, V600K, and K601E. One (3%) patient had a 
co-occurring driver mutation, which was KRAS V12 together 
with BRAF V600K. Another patient had concomitant HER2 
amplification with BRAF V600E. No co-occurring alterations 
of EGFR, ALK, MET, RET, or ROS1 were reported.
Drug Exposure
All 35 patients had at least one line of therapy with a 
known BRAF inhibitor (Table 3). Thirty-one patients received 
one BRAF inhibitor, and four patients received two different 
inhibitors, including three patients treated with vemurafenib 
followed by dabrafenib and one patient treated with sorafenib 
followed by vemurafenib. A total of 39 lines of BRAF-targeted 
therapy were administered, 29 with vemurafenib, nine with dab-
rafenib, and one with sorafenib. Drugs were prescribed at their 
registered dose, which was 960 mg twice a day for vemurafenib, 
150 mg twice a day for dabrafenib, and 400 mg for sorafenib. Five 
patients had BRAF therapy in the first line (all with vemurafenib), 
30 had BRAF therapy in further lines. Among the latter, all 30 
had platinum-based first-line chemotherapy, 21 of them with 
pemetrexed, three with paclitaxel, three with vinorelbine, and 
three with gemcitabine. Five patients had bevacizumab in addi-
tion to chemotherapy. The median number of systemic therapies 
(including BRAF-targeted therapy) was three, and the maximum 
was six. No unexpected or fatal adverse effects were reported.
Best Response with Systemic Therapy
Best response was assessed locally by RECIST1.1 
(Table 4). For BRAF therapy, one patient had missing response 
data and was excluded, 34 patients had data and were included in 
the analysis. Of the latter, one (3%) patient had nonmeasurable 
disease by response evaluation criteria in solid tumors two (6%) 
had complete response, 16 (47%) had partial response (PR), 11 
(32%) had stable disease, and 4 (11%) had progressive disease. 
ORR was 53% (95% confidence interval [CI]: 35.1–70.2), and 
disease control rate (DCR) was 85% (95% CI: 68.9–95.0). In 
TABLE 1.  Patient Characteristics
Sample size (N) 35
Age at diagnosis
  Median years (range) 63 (42–85)
Gender
  Male 18 (51%)
  Female 17 (49%)
Smoking status
  Never 14 (40%)
  Former/current 16 (46%)
  Unknown 5 (14%)
Country
  France 13 (37%)
  Switzerland 10 (28%)
  Germany 7 (20%)
  The Netherlands 4 (11%)
  Austria 1 (3%)
Systemic therapy
  Median lines (range) 3 (1–6)
  Platinum-based frontline therapy 30 (86%)
TABLE 2.  Tumor Parameters
Sample size (N) 35
NSCLC histology
  Adenocarcinoma 35 (100%)
  Other 0
Stage at initial NSCLC diagnosis
  I and II 1 (3%)
  III 4 (11%)
  IV 30 (86%)
Metastatic sites of special interest
  Malignant effusion 10 (29%)
  Brain metastases 6 (17%)
BRAF mutation
  V600E 29 (83%)
  Non-V600E 6 (17%): G466V, G469A, G469L, 
G596V, V600K, K601E
Other driver mutations
  No 34 (97%)
  Yes 1 (3%): KRAS V12
NSCLC, non–small-cell lung cancer.
TABLE 3.  Drug Exposure
Sample size (N) 35
BRAF inhibitor therapy 35 (100%)
BRAF inhibitors and lines (total) 39
  Vemurafenib 29
  Dabrafenib 9
  Sorafenib 1
Sequential BRAF inhibitors
  No 31 (89%)
  Yes 4 (11%): 3× vemurafenib →  
dabrafenib and 1× sorafenib → 
vemurafenib
BRAF inhibitor used in
  First line 5 (14%)
  Further lines 30 (86%)
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the 24 evaluable patients with BRAF V600E and vemurafenib 
therapy, ORR was 54% (95% CI: 32.8–74.4) and DCR was 96% 
(95% CI: 78.9–99.9). Among the five patients with first-line 
vemurafenib therapy, three (60%) had a response. One patient 
received sorafenib in second line and had PR. Among the 4 
patients with two BRAF-inhibitors, one (25%) had a PR with 
dabrafenib after vemurafenib. From the 6 patients with non-
V600E, one (17%) with G596V had PR with vemurafenib. ORR 
with first-line chemotherapy was 38%, no remissions were seen 
with docetaxel or erlotinib used in further lines (data not shown).
Survival and Duration of Therapy
From the entire cohort, one patient had missing survival 
data, 34 (97%) patients were evaluable for PFS and OS. For 
first-line therapy, including chemotherapy, PFS was 37 weeks 
(9.3 months) for V600E and 6 weeks (1.5 months) for non-
V600E (Fig. 1). OS was 101 weeks (25.3 months) for V600E 
and 47 weeks (11.8 months) for non-V600E. Logrank testing 
was not performed because of small sample size. For BRAF 
therapy, median PFS was 20 weeks (5.0 months; 95% CI: 
12–41 weeks), and OS was 43 weeks (10.8 months; 95% CI: 
22–96 weeks; Fig. 2). Duration of BRAF therapy was evaluable 
in 34 patients, with a median of 17 weeks (4.3 months; range, 
2–164 weeks; Fig. 3). Some patients had response evaluation 
criteria in solid tumors responses within 3–4 months after start 
of BRAF-targeted therapy (Fig. 4).
DISCUSSION
The EURAF cohort confirmed the clinically relevant 
antitumor activity of vemurafenib and dabrafenib in patients 
with advanced BRAF-mutant lung cancer, consistent with pre-
liminary reports from two phase II trials.27,28 In the vemurafenib 
basket trial (VE-BASKET) trial (NCT01524978), patients 
with solid tumors or multiple myeloma and BRAF codon 600 
mutation by local testing were treated with vemurafenib at the 
standard dose of 960 mg twice a day. So far, the investigators 
reported on 19 patients with lung cancer, of which eight (42%) 
had unconfirmed PR, and eight (42%) had stable disease, for 
an unconfirmed DCR of 84%.27 The trial BRF113928 with dab-
rafenib enrolled 84 patients with lung cancer and V600E, ORR 
in second line was 32%, DCR was 56%, and PFS 5.2 months.28 
Publication of these trials in a peer-reviewed journal is pending. 
Another phase II trial, AcSé vemurafenib (NCT02304809), is 
currently enrolling further patients in France.
In the European BRAF cohort (EURAF) cohort, we 
observed rapid and marked tumor responses in some patients 
with heavy pretreatment and advanced age. Such patients are 
generally excluded from clinical trials. Consistent with our pre-
vious “real-world” cohorts European ROS1 cohort (EUROS1) 
and European HER2 cohort (EUHER2), these results suggested 
that patients treated outside of trials can derive similar benefit 
from molecular testing and targeted therapy, as patients treated 
within trials.29,30 Moreover, EURAF included six patients with 
BRAF non-V600E mutations. Consistent with a recent U.S. 
study,19 patients with non-V600E had shorter OS than patients 
with V600E in our cohort. All tumors with non-V600E muta-
tions located outside of the activation segment of the BRAF 
kinase domain were refractory to BRAF therapy, including 
the one with G469L described previously.31 One patient with 
G596V achieved PR with vemurafenib. Consistent with pre-
clinical experiments with L597-mutant melanoma cells, this 
supported the notion that mutations located within the activa-
tion loop (codon 596 through 600) are potentially sensitive to 
TABLE 4.  Best Response with BRAF Inhibitor
All Patients  
(N = 35)
V600E and  
Vemurafenib Subgroup  
(N = 25)
Data missing 1 1
  Not measurable 1 (3%) 1 (4%)
  CR 2 (6%) 2 (8%)
  PR 16 (47%) 11 (46%)
  SD 11 (32%) 10 (42%)
  PD 4 (12%) 0
ORR 18 (53%; 95% CI: 35–70) 13 (54%; 95% CI: 33–74)
DCR 29 (85%; 95% CI: 69–95) 23 (96%; 95% CI: 79–100)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive 
disease; ORR, overall response rate; DCR, disease control rate; CI, confidence interval.
FIGURE 1.  Survival from first-line therapy: (A) progression free survival; (B) overall survival.
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BRAF inhibition.32 Although the incidence of such mutations 
is rather low, further clinical research is needed.19,20 Among 
the four patients in EURAF with two lines of targeted ther-
apy, one had a response with dabrafenib after vemurafenib, as 
reported elsewhere.24 Another group recently published a case 
with intracranial response, a finding which we did not observe, 
perhaps because (brain) imaging was not predefined in our 
retrospective study.23 Other limitations of EURAF were lack 
of central testing and lack of independent radiological review. 
However, all participating centers had accredited diagnostic 
laboratories, and all evaluations were carried out by trained and 
experienced investigators.
As expected from the literature, EURAF included 
nonsmokers and smokers.19,20 Compared with nonsmok-
ers, BRAF (and MET) mutations in smokers are among the 
most frequent recurrent oncogenic drivers for which tar-
geted therapy presently exist.33 All patients in EURAF had 
adenocarcinoma histology, supporting the current recom-
mendations for molecular testing of nonsquamous NSCLC.4 
Consistent with the Lung Cancer Mutation Consortium study, 
one (3%) patient in our study had two driver mutations in the 
same tumor.20 In the initial bronchial biopsy, only the BRAF 
V600K mutation was detected by Sanger sequencing. When 
the patient received dabrafenib, the tumor progressed with 
FIGURE 2.  Survival with BRAF therapy: (A) progression free survival; (B) overall survival.
FIGURE 3.  Duration of BRAF therapy. Legend: Bar colors indicate ongoing (black) or finished (grey) BRAF therapy. Continuous 
lines indicate vemurafenib, dashed lines dabrafenib. Patients treated with two different BRAF-inhibitors are depicted by their 
patient code (p#), each BRAF therapy is represented by a separate bar (#1 or #2). Only the non-V600E mutations are labeled, 
and all other patients had V600E.
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massive pleural effusion requiring repeated thoracocentesis. 
NGS on pleural tumor cells revealed a KRAS V12 mutation, 
which was also identified in the initial diagnostic sample by 
NGS, although with lower allele frequency. These observa-
tions may explain the lack of drug activity in a potentially 
sensitive tumor with V600K and were consistent with previ-
ous reports by others on the outgrowth of RAS-mutant clones 
under BRAF therapy and the superior sensitivity of NGS 
compared with Sanger sequencing.34,35 Other mechanisms 
of resistance to BRAF inhibitors include EGFR upregula-
tion and ERK/MEK pathway activation through CRAF.36–38 
In patients with melanoma, combined MEK and BRAF 
inhibition significantly prolonged survival, compared with 
BRAF-monotherapy.39,40 In preclinical lung cancer models, 
combination was also more active than single agent.41 A non-
randomized phase II trial with dabrafenib plus trametinib is 
currently recruiting patients with BRAF-mutant lung can-
cer (NCT01336634). Another approach to overcoming drug 
resistance in BRAF-mutant cancer is immune checkpoint 
inhibition.42 In patients with melanoma, a phase I trial with 
targeted therapy plus immunotherapy is currently ongoing 
(NCT01656642). Because EGFR-mutant lung cancer cells 
have been shown to upregulate programmed death ligand 1 
expression, such combination therapies should also be tested 
in patients with lung cancer and activating BRAF mutations.43
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